DGS Capital Management LLC Acquires 44,654 Shares of InMode Ltd. $INMD

by · The Markets Daily

DGS Capital Management LLC grew its holdings in InMode Ltd. (NASDAQ:INMD – Free Report) by 127.7% during the 4th quarter, Holdings Channel reports. The fund owned 79,613 shares of the healthcare company’s stock after buying an additional 44,654 shares during the period. DGS Capital Management LLC’s holdings in InMode were worth $1,170,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of INMD. Royal Bank of Canada increased its stake in shares of InMode by 5.7% in the 1st quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company’s stock worth $4,299,000 after purchasing an additional 13,032 shares in the last quarter. AQR Capital Management LLC purchased a new stake in InMode in the first quarter worth about $317,000. Goldman Sachs Group Inc. raised its stake in shares of InMode by 234.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after buying an additional 788,157 shares during the period. American Century Companies Inc. raised its stake in shares of InMode by 132.9% in the second quarter. American Century Companies Inc. now owns 44,240 shares of the healthcare company’s stock worth $639,000 after buying an additional 25,246 shares during the period. Finally, Marshall Wace LLP grew its stake in shares of InMode by 270.7% during the 2nd quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock valued at $8,022,000 after acquiring an additional 405,707 shares during the period. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Price Performance

InMode stock opened at $13.40 on Friday. The firm’s 50 day moving average price is $13.90 and its 200-day moving average price is $14.15. InMode Ltd. has a 1 year low of $12.72 and a 1 year high of $16.74. The stock has a market cap of $849.02 million, a P/E ratio of 9.85 and a beta of 1.94.

InMode (NASDAQ:INMD – Get Free Report) last issued its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.05). InMode had a return on equity of 13.47% and a net margin of 23.27%.The firm had revenue of $82.02 million during the quarter, compared to the consensus estimate of $79.84 million. During the same period last year, the firm posted $0.31 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year.

Analyst Upgrades and Downgrades

INMD has been the topic of a number of recent analyst reports. Barclays set a $19.00 target price on shares of InMode and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Robert W. Baird cut their price target on InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $16.00.

View Our Latest Report on INMD

InMode Company Profile

(Free Report)

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

Featured Articles

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD – Free Report).